# Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation

> **NCT01581177** · PHASE2 · COMPLETED · sponsor: **Amphastar Pharmaceuticals, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Albuterol DPI 25 mcg/inh
- **DRUG:** Albuterol DPI 90 mcg/inh
- **DRUG:** Placebo DPI
- **DRUG:** Albuterol MDI 90 mcg/inh

## Key facts

- **NCT ID:** NCT01581177
- **Lead sponsor:** Amphastar Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2012-07
- **Final completion:** 2012-08
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2017-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01581177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01581177, "Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01581177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*